An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis

References

• Kirwan JR1, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;1:CD006356.
   PubMed Web of Science ®Google Scholar
• Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52(11):3360–3370.
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329–339.
   PubMed Web of Science ®Google Scholar
• Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther. 2012;14(3):R112.
   PubMed Web of Science ®Google Scholar
• Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–293.
   PubMed Web of Science ®Google Scholar
• Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952–957.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913–1919.
   PubMed Web of Science ®Google Scholar
• Santiago T, Jacobs JW, Saag KG, et al. Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. Acta Reumatol Port. 2015;40(1):10–22.
   PubMed Web of Science ®Google Scholar
• Santiago T, Da Silva JA. Safety of glucocorticoids in rheumatoid arthritis: evidence from recent clinical trials. Neuroimmunomodulation. 2015;22(1–2):57–65.
   PubMed Web of Science ®Google Scholar
• Hwang YG, Saag K. The safety of low-dose glucocorticoids in rheumatic diseases: results from observational studies. Neuroimmunomodulation. 2015;22(1–2):72–82.
   PubMed Web of Science ®Google Scholar
• de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73(7):1331–1339.
   PubMed Web of Science ®Google Scholar
• Safy M, Jacobs J, IJff ND, et al. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second computer-assisted management in early rheumatoid arthritis trial. Ann Rheum Dis. 2017;76(8):1432–1435.
   PubMed Web of Science ®Google Scholar
• Ajeganova S, Svensson B, Hafström I, et al. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4):e004259.
   PubMed Web of Science ®Google Scholar
• Siu S, Haraoui B, Bissonnette R, et al. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken). 2015;67(6):754–764.
   PubMed Web of Science ®Google Scholar
• Black RJ, Hill CL, Lester S, et al. The association between systemic glucocorticoid use and the risk of cataract and glaucoma in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166468.
   PubMed Web of Science ®Google Scholar
• Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415–421.
   PubMed Web of Science ®Google Scholar
• Roubille C, Rincheval N, Dougados M, et al. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis. 2017;76(11):1797–1802.
   PubMed Web of Science ®Google Scholar
• Movahedi M, Beauchamp ME, Abrahamowicz M, et al. Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68(5):1089–1098.
   PubMed Web of Science ®Google Scholar
• Del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):264–272.
   PubMed Web of Science ®Google Scholar
• Best JH, Kong AM, Lenhart GM, et al. Association between glucocorticoid exposure and healthcare expenditures for potential glucocorticoid-related adverse events in patients with rheumatoid arthritis. J Rheumatol. 2018;45(3):320–328.
   PubMed Web of Science ®Google Scholar
• Jacobs JWG, Pereira DA, Silva JA. Glucocorticoids are always under suspicion - is the perception of their risks unbiased? J Rheumatol. 2018;45(3):293–296.
   PubMed Web of Science ®Google Scholar
• van Sijl AM, Boers M, Voskuyl AE, et al. Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One. 2014;9(1):e87965.
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011;78(1):23–30.
   PubMed Web of Science ®Google Scholar
• Spivey CA, Griffith J, Kaplan C, et al. A retrospective analysis of corticosteroid utilization before initiation of biologic DMARDs among patients with rheumatoid arthritis in the United States. Rheumatol Ther. 2018;5(1):255–270.
   PubMed Web of Science ®Google Scholar
• Okano T. [Bone metabolism and cardiovascular function update. Role of vitamin D in the bone and vascular intercommunication]. Clin Calcium. 2014;24(7):45–52.
   PubMedGoogle Scholar
• Lems WF, Baak MM, van Tuyl LH, et al. One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy. RMD Open. 2016;2(2):e000313.
   PubMed Web of Science ®Google Scholar
• Cheng TT, Lai HM, Yu SF, et al. The impact of low-dose glucocorticoids on disease activity, bone mineral density, fragility fractures, and 10-year probability of fractures in patients with rheumatoid arthritis. J Investig Med. 2018;66(6):1004–1007.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13(4):R139.
   PubMed Web of Science ®Google Scholar
• Cheng J, Li JB, Sun QL, et al. Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases. J Rheumatol. 2011;38(1):181–182.
   PubMed Web of Science ®Google Scholar
• Xuan D, Yu Y, Shao L, et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy – a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33(4):577–586.
   PubMed Web of Science ®Google Scholar
• Yang SS, Hung CT, Li SF, et al. Hepatitis B virus-related mortality in rheumatoid arthritis patients undergoing long-term low-dose glucocorticoid treatment: A population-based study. J Formos Med Assoc. 2018;117(7):566–571.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford). 2010;49(1):82–90.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(7):990–997.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225–229.
   PubMed Web of Science ®Google Scholar
• Schenfeld J, Iles J, Trivedi M, et al. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis. Rheumatol Int. 2017;37(7):1075–1082.
   PubMed Web of Science ®Google Scholar
• Ozen G, Pedro S, Holmqvist ME, et al. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76(5):848–854.
   PubMed Web of Science ®Google Scholar
• Den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum. 2012;64(3):639–646.
   PubMed Web of Science ®Google Scholar
• Joseph RM, Hunter AL, Ray DW, et al. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. Semin Arthritis Rheum. 2016;46(1):133–141.
   PubMed Web of Science ®Google Scholar
• Borresen SW, Klose M, Baslund B, et al. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. Eur J Endocrinol. 2017;177(4):287–295.
   PubMed Web of Science ®Google Scholar
• Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab. 2007;92(4):1326–1333.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Bijlsma JW. Glucocorticoids in rheumatoid arthritis: the picture is shaping up. Ann Rheum Dis. 2017;76(11):1785–1787.
   PubMed Web of Science ®Google Scholar
• Trampisch US, Krause D, Trampisch HJ, et al. Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. Trials. 2014;15:344.
   PubMed Web of Science ®Google Scholar
• Hartman L, Rasch LA, Klausch T, et al. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials. 2018;19(1):67.
   PubMedGoogle Scholar
• Pincus T. Electronic multidimensional health assessment questionnaire (eMDHAQ): past, present and future of a proposed single data management system for clinical care, research, quality improvement, and monitoring of long-term outcomes. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S17–S33.
   PubMed Web of Science ®Google Scholar
• Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–1913.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
   PubMed Web of Science ®Google Scholar
• Richter A, Listing J, Schneider M, et al. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(9):1667–1673.
   PubMed Web of Science ®Google Scholar
• Boers M. Observational studies on glucocorticoids are harmful! Lupus Sci Med. 2017;4(1):e000219.
   PubMed Web of Science ®Google Scholar
• Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543–546.
   PubMed Web of Science ®Google Scholar
• Jones KW. Medication risk must be balanced with benefit, not fear. Ann Pharmacother. 2010;44(4):737–739.
   PubMed Web of Science ®Google Scholar